Teva and Sanofi unveiled positive Phase IIb data on 17 December for the TL1A-targeting antibody candidate they are developing to compete against candidates from the same class at Roche and Merck & Co. in inflammatory bowel disease (IBD). On a same-day call, Teva execs asserted that their drug, duvakitug (TEV‘574/SAR447189), has produced “transformational” data in both ulcerative colitis and Crohn’s disease as the partners look ahead to planning a Phase III program.
Key Takeaways
- Teva reported that the TL1A-targeting antibody it is developing for IBD with Sanofi hit primary endpoints in ulcerative colitis and Crohn’s in a Phase IIb...
In the RELIEVE UCCD study, duvakitug met the primary endpoint of clinical remission in UC with both doses tested, 450mg and 900mg given subcutaneously every two weeks for 14 weeks....
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
